Drugs / Etrumadenant
Trials 22
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT04892875 | Dec 2023 → Dec 2025 | hypopharynx squamous cell carcinoma, larynx cancer, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | Jennifer Choe | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT05411146 | May → Jul 2022 | — | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05277012 | Feb → Mar 2022 | — | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05154136 | Oct → Dec 2021 | — | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03846310 | Apr 2019 → Nov 2024 | non-small cell lung carcinoma | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03720678 | Nov 2018 → Jan 2021 | colorectal cancer, gastroesophageal cancer | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03719326 | Oct 2018 → Jul 2021 | ovarian cancer, triple-negative breast carcinoma | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03629756 | Jul 2018 → Aug 2021 | breast cancer, castration-resistant prostate carcinoma, colorectal cancer, cutaneous neuroendocrine carcinoma +8 | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/24 trials · 1 met primary · 1 missed | ||||||
| Phase 1/2 | NCT04660812 | May 2021 → Sep 2025 | colorectal cancer | Arcus Biosciences, Inc. | Completed | Met primary |
| Phase 1/2 | NCT04381832 | Jul 2020 → Aug 2024 | castration-resistant prostate carcinoma | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03555149 | Sep 2018 → Sep 2022 | colorectal cancer | Hoffmann-La Roche | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03193190 | Jul 2017 → Feb 2025 | pancreatic adenocarcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 210 trials | ||||||
| Phase 2 | NCT06048484 | May 2024 → Apr 2027 expected | pancreatic ductal adenocarcinoma | Gulam Manji | Recruiting | No outcome recorded |
| Phase 2 | NCT05915442 | Jul 2023 → Dec 2026 expected | metastatic prostate carcinoma | Catherine Spina | Recruiting | No outcome recorded |
| Phase 2 | NCT05335941 | Jun 2023 → Sep 2027 expected | metastatic malignant neoplasm, urothelial carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05886634 | May 2023 → May 2027 expected | dedifferentiated liposarcoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05633667 | Mar 2023 → Sep 2029 expected | non-small cell lung carcinoma | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05024097 | Mar 2022 → Dec 2026 expected | rectal cancer | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 2 | NCT05177770 | Jan 2022 → Apr 2023 | castration-resistant prostate carcinoma | Coherus Oncology, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04791839 | Aug 2021 → Oct 2026 expected | non-small cell lung carcinoma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04262856 | May 2020 → Jul 2025 | non-small cell squamous lung carcinoma | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03821246 | Oct 2019 → Apr 2027 expected | prostate adenocarcinoma | David Oh | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 16
| Date | Issuer | Release |
|---|---|---|
| 2024-06-02 | Gilead Sciences | Results Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer gilead.com ↗
In Cohort B of the ARC-9 mCRC Study, Etrumadenant Plus Zimberelimab, FOLFOX Chemotherapy and Bevacizumab Significantly Reduced the Risk of Death by 63% and Risk of Disease Progression by 73% Compared to Regorafenib in a Phase 1b/2 Trial |
| 2024-06-02 | Arcus Biosciences, Inc. | Results Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer arcusbio.com ↗
In Cohort B of the ARC-9 mCRC Study, Etrumadenant Plus Zimberelimab, FOLFOX Chemotherapy and Bevacizumab Significantly Reduced the Risk of Death by 63% and Risk of Disease Progression by 73% Compared to Regorafenib in a Phase 1b/2 Trial |
| 2023-06-03 | Gilead Sciences | Results Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study gilead.com ↗
Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC |
| 2023-06-03 | Arcus Biosciences, Inc. | Results Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study arcusbio.com ↗
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. |
| 2022-12-19 | Gilead Sciences | Results Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study gilead.com ↗
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. |
| 2022-12-19 | Arcus Biosciences, Inc. | Results Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study arcusbio.com ↗
35-45% Reduction in Risk of Progression or Death and a Doubling of mPFS Were Observed in the Domvanalimab-Containing Study Arms, Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC |
| 2022-11-28 | Arcus Biosciences, Inc. | Results Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer arcusbio.com ↗
Fourth Interim Analysis Shows Continued Clinically Meaningful Differentiation Across All Efficacy Measures, Including PFS, in Both Domvanalimab-Containing Arms Compared to the Anti-PD-1 Zimberelimab Monotherapy Arm in First-Line NSCLC Patients |
| 2022-05-09 | Arcus Biosciences, Inc. | Results Arcus Biosciences Reports First Quarter 2022 Financial Results and Provides a Pipeline Update, Including from the Third Interim Analysis for the ARC-7 Study arcusbio.com ↗
In this interim analysis, both domvanalimab-containing arms continued to show meaningful differentiation compared to zimberelimab alone across multiple efficacy measures, including overall response rate (ORR) and duration of response (DoR). |
| 2022-01-10 | Arcus Biosciences, Inc. | Results Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones arcusbio.com ↗
The randomized Phase 1/1b study ARC-4 did not show differentiated clinical activity for etrumadenant plus zimberelimab and pemetrexed/carboplatin compared to that of zimberelimab and pemetrexed/carboplatin in patients with metastatic, EGFRm+ NSCLC who progressed after one or more TKI therapies. |
| 2021-11-08 | Arcus Biosciences, Inc. | Results Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab arcusbio.com ↗
Both domvanalimab-containing arms demonstrated differentiated clinical activity compared to that of zimberelimab alone in a second interim analysis of ARC-7, our randomized Phase 2 study in first-line metastatic non-small cell lung cancer (NSCLC) |
| 2021-05-19 | Arcus Biosciences, Inc. | Results Arcus Biosciences Presents Early Data from ARC-6, a Phase 1b/2 Study Evaluating Etrumadenant-Based Combinations in Metastatic Castrate-Resistant Prostate Cancer at the 2021 ASCO Annual Meeting arcusbio.com ↗
In this Phase 1b cohort of the etrumadenant-based combination, a composite ORR (radiographic and/or PSA [prostate-specific antigen] response) of 41% and a PSA response of 35% were observed. |
| 2021-04-10 | Arcus Biosciences, Inc. | Results Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting arcusbio.com ↗
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented progression-free survival (PFS) and overall survival (OS) data in patients with advanced metastatic colorectal cancer (mCRC) from the ARC-3 study at the 2021 American Association for Cancer Research (AACR) Annual Meeting. |
| 2018-10-08 | Arcus Biosciences, Inc. | Results Arcus Biosciences to Present Final Results from the Phase 1 Study of AB928 in Healthy Volunteers at ESMO 2018 Congress arcusbio.com ↗
The safety data to be presented will demonstrate that in this study, there was no evidence of the physiological effects of blocking adenosine that have been observed clinically with earlier adenosine receptor antagonists. |
| 2018-07-17 | Arcus Biosciences, Inc. | Results Arcus Biosciences Announces Final Safety Results From Phase 1 Trial for AB928 in Healthy Volunteers arcusbio.com ↗
These results demonstrated that AB928 was safe and well tolerated at all doses evaluated. |
| 2018-06-11 | Arcus Biosciences, Inc. | Regulatory Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations arcusbio.com ↗
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared Investigational New Drug (IND) applications for the Company’s two most advanced product candidates, AB928 and AB122. |
| 2018-04-17 | Arcus Biosciences, Inc. | Results Arcus Biosciences Presents Phase 1 Data for AB928 in Healthy Volunteers at 2018 AACR Annual Meeting arcusbio.com ↗
The compound has been shown to be safe and well tolerated at all doses evaluated and achieves near complete inhibition of A 2a R adenosine receptor activation in blood samples from healthy volunteers |
All press releases naming this drug 20 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | etrumadenant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05177770 ↗ |
| Known as | AB928 | “Etrumadenant (AB928)” NCT05024097 ↗ |
| Action | Inhibit | “Etrumadenant is an A2aR and A2bR antagonist.” NCT03629756 ↗2“Adenosine A2b receptor antagonist” CHEMBL4740383 ↗ “Adenosine A2a receptor antagonist” CHEMBL4740383 ↗ |
| Modality | Small molecule | — CHEMBL4740383 ↗ |
| Route | Oral | “AB928 150 mg orally once daily on Days 1 to 28 of each 28 day cycle” NCT03193190 ↗ |
| Target | ADORA2A | “Adenosine A2a receptor antagonist” CHEMBL4740383 ↗ |
| Target | ADORA2B | “Adenosine A2b receptor antagonist” CHEMBL4740383 ↗ |